Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
CD19 CAR-T is now a validated option in relapsed/refractory Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL), with lisocabtagene maraleucel (liso-cel, Breyanzi) becoming the first FDA-approved CAR-T for this disease in March 2024 after prior BTK- and BCL2-inhibitor exposure. In CLL/SLL, its role is mainly for heavily pretreated, high-risk patients rather than earlier-line routine use
In patients with advanced [Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)](brain://qkQ4iAedT…